antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-3-4-77-84antibiotics-916Research ArticleОБЗОРЫREVIEWSАнтибиотикотерапия бруцеллёза. Cовременное состояние и перспективы совершенствованияAntibiotic Therapy of Brucellosis. Current State and Prospects for Improvementhttps://orcid.org/0000-0001-6263-8155ЩипелеваИ. А.ShchipelevaI. A.

 Щипелева Ирина Александровна — к. б. н., начальникнаучного отдела — учёный секретарь

 eLIBRARY SPINкод: 4067-8591, Scopus Author ID: 22958485500 

 ул. М. Горького, д. 117/40, г. Ростов-наДону, 344002.

 Irina A. Shchipeleva — Ph. D. in biolog

eLIBRARY SPIN: 4067-8591, Scopus Author ID: 22958485500 

 117/40 M.Gorkogo st., Rostov-on-Don, 344002  

markovskay2014@yndex.ruhttps://orcid.org/0000-0002-5360-951XМарковскаяЕ. И.MarkovskayaE. I.

 Марковская Елена Ивановна — к. м. н., старший научныйсотрудник

ул. М. Горького, д. 117/40, г. Ростов-наДону, 344002.

 Elena I. Markovskaya — Ph. D. in medicine

 117/40 M.Gorkogo st., Rostov-on-Don, 344002  

https://orcid.org/0000-0001-5299-0243КретенчукО. Ф.KretenchukО. F.

 Кретенчук Оксана Фёдоровна — к. б. н., старший научный сотрудник

 eLIBRARY SPIN-код: 6275-4113 

ул. М. Горького, д. 117/40, г. Ростов-наДону, 344002.

 Oksana F. Kretenchuk — Ph. D. in biology

 eLIBRARY SPIN: 6275-4113 

117/40 M.Gorkogo st., Rostov-on-Don, 344002  

ФКУЗ Ростовский-на-Дону научно-исследовательский противочумный институт РоспотребнадзораРоссияRostov-on-Don Plague Control Research Institute of the Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian Federation202205082022673-47784Copyright © Щипелева И.А., Марковская Е.И., Кретенчук О.Ф., 20222022Щипелева И.А., Марковская Е.И., Кретенчук О.Ф.Shchipeleva I.A., Markovskaya E.I., Kretenchuk О.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/916

Бруцеллёз человека — особо опасная социально значимая инфекция, по-прежнему представляющая серьёзную угрозу для здоровья населения, в связи с широким спектром клинических проявлений, тяжёлым течением и развитием серьёзных осложнений инфекции, приводящих к инвалидизации, что в свою очередь приносит значительный ущерб экономике. Вопросы лечения остаются дискуссионной проблемой, так как способность возбудителя к внутриклеточному паразитированию осложняет проведение эффективной антибиотикотерапии.

В обзоре представлены данные об активности in vitro и эффективности при использовании в качестве средств монотерапии тетрациклинов, рифампицина, фторхинолонов, аминогликозидов, карбапенемов, макролидов, цефалоспоринов, хлорамфеникола и триметоприма/сульфаметоксазола. Приведены данные об эффективности использования антибактериальных препаратов в различных комбинациях, о включении в схему лечения иммуномодуляторов. Рассмотрена информация о перспективных современных разработках, способствующих лучшему проникновению антибактериальных препаратов в фагоцитарные клетки. Представлены некоторые результаты поиска источников новых средств антибактериальной терапии бруцеллёза.

Human brucellosis is a particularly dangerous socially significant infection that still poses a serious threat to public health due to a wide range of clinical manifestations, severe course, and the development of serious complications of infection that may lead to disability, which, in turn, causes significant damage to the economy. Treatment issues remain debatable, since the pathogen's ability to cause intracellular parasitism complicates effective antibiotic therapy. The review presents the data on in vitro activity and effic acy when using tetracyclines, rifampicin, fluoroquinolones, aminoglycosides, carbapenems, macrolides, cephalosporins, chloramphenicol, and trimethoprim/sulfamethoxazole as monotherapy agents. The data on the effectiveness of the use of antibacterial drugs in various combinations, and the inclusion of immunomodulators in the treatment regimen are presented. Information concerning promising modern developments that facilitate better penetration of antibacterial drugs into phagocytic cells is considered. Some results of searching for sources of new means of antibacterial therapy of brucellosis are presented.

BrucellaбруцеллёзантибиотикилечениерезистентностьBrucellabrucellosisantibioticstreatmentresistance.ReferencesPappas G., Papadimitriou P., Akritidis N., Christou L., Tsianos E. The new global map of human brucellosis. Lancet Charge Dis. 2006; 6 (2): 91–99. doi: 10.1016/S1473-3099(06)70382-6.Pappas G., Papadimitriou P., Akritidis N., Christou L., Tsianos E. The new global map of human brucellosis. Lancet Charge Dis. 2006; 6 (2): 91–99. doi: 10.1016/S1473-3099(06)70382-6.Бруцеллёз. Современное состояние проблемы. Под ред. Г. Г. Онищенко, А. Н. Куличенко. Ставрополь: ООО «Губерния»; 2019.Brucellosis. The current state of the problem. G.G.Onishchenko, A.N.Kulichenko. Stavropol: OOO «Gubernia»; 2019. (in Russian)]Głowacka P., Rakowska D., Naylor K., Niemcewicz M., Bielawska-Drózd A. Brucella — virulence factors, pathogenesis and treatment. Pol J Microbiol. 2018; 67 (2): 151–161. doi: 10.21307/pjm-2018-029.Głowacka P., Rakowska D., Naylor K., Niemcewicz M., Bielawska-Drózd A. Brucella — virulence factors, pathogenesis and treatment. Pol J Microbiol. 2018; 67 (2): 151–161. doi: 10.21307/pjm-2018-029.МУК 4.2.3010-12 Порядок организации и проведения лабораторной диагностики бруцеллёза для лабораторий территориального, регионального и федерального уровней. М.: 2012.MUK 4.2.3010-12 Poryadok organizatsii i provedeniya laboratornoi diagnostiki brutselleza dlya laboratorii territorial'nogo, regional'nogo i federal'nogo urovnei. Moscow: 2012. (in Russian)]Figueiredo P.D., Ficht T.A., Rice-Ficht A., Rossetti C.A., Adams L.G. Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. J Pathol. 2015; 185 (6): 1505–17. doi: 10.1016/j.ajpath.2015.03.003.Figueiredo P.D., Ficht T.A., Rice-Ficht A., Rossetti C.A., Adams L.G. Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. J Pathol. 2015; 185 (6): 1505–17. doi: 10.1016/j.ajpath.2015.03.003.Bossi P., Tegnell A., Baka A., Van Loock F., Hendriks J., Werner A. et al. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill. 2004; 15 (9 (12)): E15–16.doi: 10.2807/esm.09.12.00506-en.Bossi P., Tegnell A., Baka A., Van Loock F., Hendriks J., Werner A. et al. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill. 2004; 15 (9 (12)): E15–16.doi: 10.2807/esm.09.12.00506-en.Сыздыков М.С., Кузнецов А.Н., Дуйсенова А.К., Шевцов А.Б. Фенотипические свойства и чувствительность к антибактериальным препаратам клинических изолятов бруцелл, выделенных в Казахстане. Вестник КазНМУ. 2016; 3: 32–35.Syzdykov M.S., Kuznetsov A.N., Duisenova A.K., Shevtsov A.B. Fenotipicheskie svoistva i chuvstvitel'nost' k antibakterial'nym preparatam klinicheskikh izolyatov brutsell, vydelennykh v Kazakhstane. Vestnik KazNMU. 2016; 3: 32–35.]Liu Z.G., Di D.D., Wang M., Liu R.H., Zhao H.Y., Piao D.R. et al. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China. BMC Infect Dis. 2018; 18 (1): 43. doi: 10.1186/s12879-018-2947-6.Liu Z.G., Di D.D., Wang M., Liu R.H., Zhao H.Y., Piao D.R. et al. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China. BMC Infect Dis. 2018; 18 (1): 43. doi: 10.1186/s12879-018-2947-6.Ozhak-Baysan B., Ongut G., Ogunc D., Gunseren F., Sepin-Ozen N., Ozturk F. et al. Evaluation of in vitro activities of tigecycline and various antibiotics against Brucella spp. Polish journal of microbiology. 2010; 59 (1):55–60. doi: 10.33073/pjm-2010-008.Ozhak-Baysan B., Ongut G., Ogunc D., Gunseren F., Sepin-Ozen N., Ozturk F. et al. Evaluation of in vitro activities of tigecycline and various antibiotics against Brucella spp. Polish journal of microbiology. 2010; 59 (1):55–60. doi: 10.33073/pjm-2010-008.Bayram Y., Korkoca H., Aypak C., Parlak M., Cikman A., Kilic S. et al. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci. 2011; 8 (3): 198–202. doi: 10.7150/ijms.8.198.Bayram Y., Korkoca H., Aypak C., Parlak M., Cikman A., Kilic S. et al. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci. 2011; 8 (3): 198–202. doi: 10.7150/ijms.8.198.Gutiérrez A.A., Díez Enciso M., Peña García P., Campos Bueno A. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline,and co-trimoxazole. Antimicrob Agents Chemother. 1982; 21 (3): 501–3.doi: 10.1128/AAC.21.3.501.Gutiérrez A.A., Díez Enciso M., Peña García P., Campos Bueno A. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline,and co-trimoxazole. Antimicrob Agents Chemother. 1982; 21 (3): 501–3.doi: 10.1128/AAC.21.3.501.Shevtsov A., Syzdykov M., Kuznetsov A., Shustov A., Shevtsova E., Berdimuratova K. et al. Antimicrobial susceptibility of Brucella melitensis in Kazakhstan. Antimicrob Resist Infect Control. 2017; 6: 130. doi:10.1186/s13756-017-0293-x.Shevtsov A., Syzdykov M., Kuznetsov A., Shustov A., Shevtsova E., Berdimuratova K. et al. Antimicrobial susceptibility of Brucella melitensis in Kazakhstan. Antimicrob Resist Infect Control. 2017; 6: 130. doi:10.1186/s13756-017-0293-x.Garcia-Rodriguez J.A., Garcia-Sanchez J.E., Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 1991; 35: 756–759. doi: 10.1128/AAC.35.4.756.Garcia-Rodriguez J.A., Garcia-Sanchez J.E., Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 1991; 35: 756–759. doi: 10.1128/AAC.35.4.756.Rubinstein E., Lang R., Shasha B., Hagar B., Diamantstein L., Joseph G. et al. In vitro susceptibility Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991; 35 (9): 1925–1927. doi: 10.1128/AAC.35.9.1925Rubinstein E., Lang R., Shasha B., Hagar B., Diamantstein L., Joseph G. et al. In vitro susceptibility Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991; 35 (9): 1925–1927. doi: 10.1128/AAC.35.9.1925\Малецкая О.В. Эффективность некоторых новых антибиотиков при лечении экспериментального бруцеллёза. Антибиотики и химиотер. 2002; 47 (11): 4–7.Maletskaya O.V. Effektivnost' nekotorykh novykh antibiotikov pri lechenii eksperimental'nogo brutselleza. Antibiotiki i khimioter. 2002; 47 (11): 4–7. (in Russian)]Kocagöz S., Akova M., Altun B., Gür D., Hasçelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect. 2002; 8 (4): 240–242. doi: 10.1046/j.1469-0691.2002.00416.x.Kocagöz S., Akova M., Altun B., Gür D., Hasçelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect. 2002; 8 (4): 240–242. doi: 10.1046/j.1469-0691.2002.00416.x.López-Merino A., Contreras-Rodríguez A., Migranas-Ortiz R., OrrantiaGradín R., Hernández-Oliva G.M., Gutiérrez-Rubio A.T. et al. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004; 36 (9): 636–638. doi: 10.1080/00365540410020767.López-Merino A., Contreras-Rodríguez A., Migranas-Ortiz R., OrrantiaGradín R., Hernández-Oliva G.M., Gutiérrez-Rubio A.T. et al. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004; 36 (9): 636–638. doi: 10.1080/00365540410020767.Mc Devitt D.G. Ampicillin in the treatment of brucellosis. A controlled therapeutic trial. Br J Ind Med. 1970; 27: 67–71.Mc Devitt D.G. Ampicillin in the treatment of brucellosis. A controlled therapeutic trial. Br J Ind Med. 1970; 27: 67–71.Turkmani A., Ioannidis A., Christidou A., Psaroulaki A., Loukaides F., Tselentis Y. In vitro susceptibility of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob. 2006; 5(1): 24. doi:10.1186/1476-0711-5-24.Turkmani A., Ioannidis A., Christidou A., Psaroulaki A., Loukaides F., Tselentis Y. In vitro susceptibility of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob. 2006; 5(1): 24. doi:10.1186/1476-0711-5-24.Alamian Saeed, Dadar Maryam, Etemadi Avshar, Davoud Afshar, Alamian Mohammad Mehdi. Antimicrobial susceptibility of Brucella spp. isolated from Iranian patients between 2016 and 2018. Iran J Microbiol. 2019; 11 (5): 363–367. doi: 10.18502/ijm.v11i5.1953.Alamian Saeed, Dadar Maryam, Etemadi Avshar, Davoud Afshar, Alamian Mohammad Mehdi. Antimicrobial susceptibility of Brucella spp. isolated from Iranian patients between 2016 and 2018. Iran J Microbiol. 2019; 11 (5): 363–367. doi: 10.18502/ijm.v11i5.1953.Lang R., Dagan R., Potasman I., Einhorn M., Raz R. Failure of ceftriaxone in the treatment of acute brucellosis. Clin Infect Dis. 1992; 14 (2): 506–509. doi: 10.1093/clinids/14.2.506.Lang R., Dagan R., Potasman I., Einhorn M., Raz R. Failure of ceftriaxone in the treatment of acute brucellosis. Clin Infect Dis. 1992; 14 (2): 506–509. doi: 10.1093/clinids/14.2.506.Baykam N., Esenin N., Ergonul О., Eren S., Chelikbas A.K., Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 2004; 23 (4): 405–407. doi: 10.1016/j.ijantimicag.2003.09.024.Baykam N., Esenin N., Ergonul О., Eren S., Chelikbas A.K., Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 2004; 23 (4): 405–407. doi: 10.1016/j.ijantimicag.2003.09.024.Marianelli C., Ciuchini F., Tarantino M., Pasquali P., Adone R. Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol. 2005; 42 (12): 5439–5443. doi: 10.1128/JCM.42.12.5439-5443.2004.Marianelli C., Ciuchini F., Tarantino M., Pasquali P., Adone R. Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol. 2005; 42 (12): 5439–5443. doi: 10.1128/JCM.42.12.5439-5443.2004.Meng F., Pan X., Tong W. Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials. PLoS ONE 1 [serial online]. 2018; 3 (2): e0191993. doi: 10.1371/journal.pone.0191993.Meng F., Pan X., Tong W. Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials. PLoS ONE 1 [serial online]. 2018; 3 (2): e0191993. doi: 10.1371/journal.pone.0191993.Godefroid M., Svensson M.V., Cambier P., Uzureau S., Mirabella A., De Bolle X. et al. Brucella melitensis 16M produces a mannan and other extracellular matrix components typical of a biofilm FEMS Immunol. Med. Microbiol. 2010; 20; 59 (3): 364–377. doi: 10.1111/j.1574-695X.2010.00689.x.Godefroid M., Svensson M.V., Cambier P., Uzureau S., Mirabella A., De Bolle X. et al. Brucella melitensis 16M produces a mannan and other extracellular matrix components typical of a biofilm FEMS Immunol. Med. Microbiol. 2010; 20; 59 (3): 364–377. doi: 10.1111/j.1574-695X.2010.00689.x.Nunan T.O., Eykyn S.J., Jones N.F. Brucellosis with mesangial IgA nephropathy: successful treatment with doxycycline and rifampicin. Br Med Jl (Clin Res Ed.). 1984; 288 (6433): 1802. doi: 10.1136/bmj.288.6433.1802.Nunan T.O., Eykyn S.J., Jones N.F. Brucellosis with mesangial IgA nephropathy: successful treatment with doxycycline and rifampicin. Br Med Jl (Clin Res Ed.). 1984; 288 (6433): 1802. doi: 10.1136/bmj.288.6433.1802.Pappas G., Solera J., Akritidis N., Tsianos E. New approaches to the antibiotic treatment of brucellosis. Intern J Antimicrobl Agents. 2005; 26 (2):101–105. doi: 10.1016/j.ijantimicag.2005.06.001.Pappas G., Solera J., Akritidis N., Tsianos E. New approaches to the antibiotic treatment of brucellosis. Intern J Antimicrobl Agents. 2005; 26 (2):101–105. doi: 10.1016/j.ijantimicag.2005.06.001.Ranjbar M. Treatment of brucellosis. Additional information is available at the end of the chapter. 2015; 171–184. doi: 10.5772/61093.Ranjbar M. Treatment of brucellosis. Additional information is available at the end of the chapter. 2015; 171–184. doi: 10.5772/61093.Gómez-Reino F.J., Mateo I., Fuertes A., Gómez-Reino J.J. Brucellar arthritis in children and its successful treatment with trimethoprim-sulphamethoxazole (co-trimoxazole). Ann Rheum Dis. 1986; 45 (3): 256–258. doi: 10.1136/ard.45.3.256.Gómez-Reino F.J., Mateo I., Fuertes A., Gómez-Reino J.J. Brucellar arthritis in children and its successful treatment with trimethoprim-sulphamethoxazole (co-trimoxazole). Ann Rheum Dis. 1986; 45 (3): 256–258. doi: 10.1136/ard.45.3.256.Патент РФ на изобретение №2206898, 20.06.03. Малецкая О.В., Логвиненко О.В., Лямкин Г.И., Ляпустина Л.В., Соколова И.А. Способ контроля эффективности антибиотика при лечении бруцеллёза. Доступно по: javascript:load_article(37914988). Ссылка активна на 12.06.2020.Patent RUS №2206898, 20.06.03. Maletskaja O.V., Logvinenko O.V., Ljamkin G.I., Ljapustina L.V., Sokolova I.A. Method for control of antibiotic efficiency in treatment of brucellosis. Dostupno po: javascript:load_article(37914988). Ssylka aktivna na 12.06.2020. (in Russian)]]Al-Sibai M.B., Halim M.A., El-Shaker M.M., Khan B.A., Qadri S.M. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother. 1992; 36 (1): 150–152. doi: 10.1128/AAC.36.1.150.Al-Sibai M.B., Halim M.A., El-Shaker M.M., Khan B.A., Qadri S.M. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother. 1992; 36 (1): 150–152. doi: 10.1128/AAC.36.1.150.Еренчина Э.Р., Эйсмонт А.Р., Утешева Н.М. Этиотропная терапия острого бруцеллёза и эрадикация бруцелл. Вестник Казахского национального медицинского университета. 2015; 2: 237–240.Erenchina E.R., Eismont A.R., Utesheva N.M. Etiotropnaya terapiya ostrogo brutselleza i eradikatsiya brutsell. Vestnik Kazakhskogo Natsional'nogo Meditsinskogo Universiteta. 2015; 2: 237–40.Akova M., Uzun O., Akalin H.E., Hayran M., Unal S., Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother. 1993; 37 (9): 1831–1834. doi: 10.1128/AAC.37.9.1831.Akova M., Uzun O., Akalin H.E., Hayran M., Unal S., Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother. 1993; 37 (9): 1831–1834. doi: 10.1128/AAC.37.9.1831.Pappas G., Christou L., Akritidis N., Tsianos E.V. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect. 2006; 12 (9): 823–825. doi: 10.1111/j.1469-0691.2006.01442.x.Pappas G., Christou L., Akritidis N., Tsianos E.V. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect. 2006; 12 (9): 823–825. doi: 10.1111/j.1469-0691.2006.01442.x.Lang R., Shasha B., Rubinstein E. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother. 1993; 37 (11):2333–2336. doi: 10.1128/aac.37.11.2333.Lang R., Shasha B., Rubinstein E. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother. 1993; 37 (11):2333–2336. doi: 10.1128/aac.37.11.2333.Artan С., Özbal Y. Comparison of the effectiveness of doxycycline and levofloxacin in an experimental model of mouse brucellosis. Nobel medicus. 2011; 7 (1): 56–60.Artan С., Özbal Y. Comparison of the effectiveness of doxycycline and levofloxacin in an experimental model of mouse brucellosis. Nobel medicus. 2011; 7 (1): 56–60.Felek S., Demirdag K., Kalkan A., Akbulut A. Therapeutic effects of rifampin and erythromycin in experimental murine brucellosis. Clin Microbiol Infect. 2000; 6 (2): 111–114. doi: 10.1046/j.1469-0691.2000.00016-4.x.Felek S., Demirdag K., Kalkan A., Akbulut A. Therapeutic effects of rifampin and erythromycin in experimental murine brucellosis. Clin Microbiol Infect. 2000; 6 (2): 111–114. doi: 10.1046/j.1469-0691.2000.00016-4.x.Qadri S.M., Halim M.A., Ueno Y., Abumustafa F.M., Postle A.G. Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy. 1995; 41 (4): 253–256. doi:10.1159/000239353.Qadri S.M., Halim M.A., Ueno Y., Abumustafa F.M., Postle A.G. Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy. 1995; 41 (4): 253–256. doi:10.1159/000239353.Solera J., Beato J.L., Martinez-Alfaro E., Segura J.C., de Tomas E. et al. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis. 2001; 32: 506–509. doi: 10.1086/318503.Solera J., Beato J.L., Martinez-Alfaro E., Segura J.C., de Tomas E. et al. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis. 2001; 32: 506–509. doi: 10.1086/318503.Rizzo-Naudi J., Griscti-Soler N., Ganado W. Human brucellosis: an evaluation of antibiotics in the treatment of brucellosis. Postgrad Med J. 1967; 43: 520–526. doi: 10.1136/pgmj.43.502.520.Rizzo-Naudi J., Griscti-Soler N., Ganado W. Human brucellosis: an evaluation of antibiotics in the treatment of brucellosis. Postgrad Med J. 1967; 43: 520–526. doi: 10.1136/pgmj.43.502.520.Salih S.B., Kharal M., Qahtani M., Dahneem L, Nohair S. Acute interstitial nephritis induced by intermittent use of rifampicin in patient with brucellosis. Saudi J Kidney Dis Transpl. 2008; 19 (3): 450–452.Salih S.B., Kharal M., Qahtani M., Dahneem L, Nohair S. Acute interstitial nephritis induced by intermittent use of rifampicin in patient with brucellosis. Saudi J Kidney Dis Transpl. 2008; 19 (3): 450–452.Abramson O., Abu-Rashid M., Gorodischer R., Yagupsky P. Failure of short antimicrobial treatments for human brucellosis. Antimicrob Agents Chemother. 1997; 41 (7): 1621–1622. doi: 10.1128/AAC.41.7.1621.Abramson O., Abu-Rashid M., Gorodischer R., Yagupsky P. Failure of short antimicrobial treatments for human brucellosis. Antimicrob Agents Chemother. 1997; 41 (7): 1621–1622. doi: 10.1128/AAC.41.7.1621.Masoomeh Sofian M., Velayati A.A., Aghakhani A., McFarland W., Farazi A.A., Banifazl M. et al. Comparison of two durations of triple-drug therapy in patients with uncomplicated brucellosis: A randomized controlled trial. Scandinavian J Infect Dis. 2014; 46 (8): 573–577. doi: 10.3109/00365548.2014.918275.Masoomeh Sofian M., Velayati A.A., Aghakhani A., McFarland W., Farazi A.A., Banifazl M. et al. Comparison of two durations of triple-drug therapy in patients with uncomplicated brucellosis: A randomized controlled trial. Scandinavian J Infect Dis. 2014; 46 (8): 573–577. doi: 10.3109/00365548.2014.918275.Solis J., del Pozo G., Solers J. Treatment of human brucellosis — a review of data from clinical trials. In book: Updates on brucellosis, Publisher: Intech, Ed. Manal Mohammad Baddou. 2015; 185–99. doi: 10.5772/61223.Solis J., del Pozo G., Solers J. Treatment of human brucellosis — a review of data from clinical trials. In book: Updates on brucellosis, Publisher: Intech, Ed. Manal Mohammad Baddou. 2015; 185–99. doi: 10.5772/61223.Taghvaee M.R., Nozadi M.S., Hassani M. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Indian J Med Sci. 2011; 65 (10): 436–443.Taghvaee M.R., Nozadi M.S., Hassani M. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. Indian J Med Sci. 2011; 65 (10): 436–443.Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother. 1985; 28 (4): 548–551. doi: 10.1128/AAC.28.4.548.Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother. 1985; 28 (4): 548–551. doi: 10.1128/AAC.28.4.548.Colmenero J.D., Fernández-Gallardo L.C., Agúndez J.A., Sedeño J., Benítez J., Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994; 38 (12): 2798–2802. doi: 10.1128/AAC.38.12.2798.Colmenero J.D., Fernández-Gallardo L.C., Agúndez J.A., Sedeño J., Benítez J., Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994; 38 (12): 2798–2802. doi: 10.1128/AAC.38.12.2798.Solera J., Rodríguez-Zapata M., Geijo P., Largo J., Paulino J., Sáez L. et al. Doxycycline — rifampin versus doxycycline — streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother. 1995; 39 (9): 2061–2067. doi:10.1128/aac.39.9.2061.Solera J., Rodríguez-Zapata M., Geijo P., Largo J., Paulino J., Sáez L. et al. Doxycycline — rifampin versus doxycycline — streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother. 1995; 39 (9): 2061–2067. doi:10.1128/aac.39.9.2061.Cisneros J.M., Viciana P., Colmenero J., Pachón J., Martinez C., Alarcón A. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother. 2017; 34 (5): 881–883. doi: 10.1128/AAC.34.5.881.Cisneros J.M., Viciana P., Colmenero J., Pachón J., Martinez C., Alarcón A. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother. 2017; 34 (5): 881–883. doi: 10.1128/AAC.34.5.881.Mani S.S.R., Gunasekaran K., Iyyadurai R., Prakash J.A.J., Veeraraghavan B., Mishra A.K. et al. Clinical spectrum, susceptibility profile, treatment and outcome of culture-confirmed brucellosis from South India. Indian J Med Microbiol. 2018; 36 (2): 289–292. doi: 10.4103/ijmm.IJMM_18_236.Mani S.S.R., Gunasekaran K., Iyyadurai R., Prakash J.A.J., Veeraraghavan B., Mishra A.K. et al. Clinical spectrum, susceptibility profile, treatment and outcome of culture-confirmed brucellosis from South India. Indian J Med Microbiol. 2018; 36 (2): 289–292. doi: 10.4103/ijmm.IJMM_18_236.Solera J., Espinosa A., Martínez-Alfaro E., Sánchez L., Geijo P., Navarro E. et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother. 1997; 41 (1): 80–84. doi: 10.1128/AAC.41.1.80.Solera J., Espinosa A., Martínez-Alfaro E., Sánchez L., Geijo P., Navarro E. et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother. 1997; 41 (1): 80–84. doi: 10.1128/AAC.41.1.80.Skalsky K., Yahav D., Bishara J., Pitlik S., Leibovici L., Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008; 336 (7646): 701–704. doi: 10.1136/bmj. 39497.500903.25.Skalsky K., Yahav D., Bishara J., Pitlik S., Leibovici L., Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008; 336 (7646): 701–704. doi: 10.1136/bmj. 39497.500903.25.Unuvar G.K., Kilic A.U., Doganay M. Current therapeutic strategy in osteoarticular brucellosis. North Clin Istanb. 2019; 6 (4): 415–420. doi:10.14744/nci.2019.05658.Unuvar G.K., Kilic A.U., Doganay M. Current therapeutic strategy in osteoarticular brucellosis. North Clin Istanb. 2019; 6 (4): 415–420. doi:10.14744/nci.2019.05658.Llorens-Terol J., Busquets R.M. Brucellosis treated with rifampicin. Arch Dis Child [serial online]. 1980; 55 (6): 486–488. doi: 10.1136/adc.55.6.486.Llorens-Terol J., Busquets R.M. Brucellosis treated with rifampicin. Arch Dis Child [serial online]. 1980; 55 (6): 486–488. doi: 10.1136/adc.55.6.486.Liu Z., Shen T., Wei D., Yu Y., Huang D., Guan P. Analysis of the epidemiological, clinical characteristics, treatment and prognosis of human brucellosis during 2014–2018 in Huludao, China. Infect Drug Resist. 2020; 13: 435–445. doi: 10.2147/IDR.S236326.Liu Z., Shen T., Wei D., Yu Y., Huang D., Guan P. Analysis of the epidemiological, clinical characteristics, treatment and prognosis of human brucellosis during 2014–2018 in Huludao, China. Infect Drug Resist. 2020; 13: 435–445. doi: 10.2147/IDR.S236326.Karabay O., Sencan I., Kayas D., Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis. 2004; 4 (1): 18. doi: 10.1186/1471-2334-4-18.Karabay O., Sencan I., Kayas D., Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis. 2004; 4 (1): 18. doi: 10.1186/1471-2334-4-18.Alp E., Koc R.K., Durak A.C., Yildiz O., Aygen B., Sumerkan B. et al. Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis. BMC Infect Dis. 2006; 6 (1): 72. doi: 10.1186/1471-2334-6-72.Alp E., Koc R.K., Durak A.C., Yildiz O., Aygen B., Sumerkan B. et al. Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis. BMC Infect Dis. 2006; 6 (1): 72. doi: 10.1186/1471-2334-6-72.Hashemi S.H., Gachkar L., Keramat F., Mamani M., Hajilooi M., Janbakhsh A. et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis. 2012; 16 (4): 247–251. doi:10.1016/j.ijid.2011.12.003.Hashemi S.H., Gachkar L., Keramat F., Mamani M., Hajilooi M., Janbakhsh A. et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis. 2012; 16 (4): 247–251. doi:10.1016/j.ijid.2011.12.003.Kilic S., Dizbay M., Hizel K., Arman D. In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology. Braz J Microbiol. 2008; 39 (2): 233–237. doi: 10.1590/S1517-83822008000200006.Kilic S., Dizbay M., Hizel K., Arman D. In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology. Braz J Microbiol. 2008; 39 (2): 233–237. doi: 10.1590/S1517-83822008000200006.Alavi S.M., Alavi L. Treatment of brucellosis: a systematic review of research over the past twenty years. Caspian J Intern Med. 2013; 4 (2):636–641.Alavi S.M., Alavi L. Treatment of brucellosis: a systematic review of research over the past twenty years. Caspian J Intern Med. 2013; 4 (2):636–641.Abed N., Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014; 43 (6): 485–496. doi: 10.1016/j.ijantimicag.2014.02.009.Abed N., Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014; 43 (6): 485–496. doi: 10.1016/j.ijantimicag.2014.02.009.Исмаилова Г.К., Жилченко Е.Б., Ефременко Д.В., Головченко Т.В., Малецкая О.В., Одинец А.В. и др. Эффективность применения липосомальных форм антибиотиков при лечении некоторых инфекционных заболеваний в эксперименте. Вестник Волгоградского государственного медицинского университета. 2007; 1 (21): 69–72.Ismailova G.K., Zhilchenko E.B., Efremenko D.V., Golovchenko T.V., Maletskaya O.V., Odinets A.V. et al. Efficiency of liposomal antibiotics in treatment of experimental infectious diseases. Journal Volgograd State Medical University. 2007; 1 (21): 69–72. (in Russian)]Малецкая О.В., Таран Т.В., Ефременко В.И., Лямкин Г.И., Мисетова Е.Н., Умнов А.В. и др. Новые подходы к лечению бруцеллёза. Эпидемиология и инфекционные болезни. 2003; 6: 34–36. [Maletskaya O.V., Taran T.V., Yefremenko V.I., Lyamkin G.I., Misetova Ye.N., Umnov A.V. et al. New approaches to treating brucellosis Epidemiology and Infectious Diseases. 2003; 6: 34–36. (in Russian)].Ха A.J., Квон Y.J. «Nanoantibiotics»: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011; 156 (2): 128–145. doi: 10.1016/j.jconrel.2011.07.002.Ха A.J., Квон Y.J. «Nanoantibiotics»: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011; 156 (2): 128–145. doi: 10.1016/j.jconrel.2011.07.002.Lecaroz M.C., Blanco-Prieto M.J., Campanero M.A., Salman H., Gamazo C. Poly (D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob Agents Chemother. 2007; 51 (4): 1185–1190. doi: 10.1128/AAC.00809-06.Lecaroz M.C., Blanco-Prieto M.J., Campanero M.A., Salman H., Gamazo C. Poly (D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob Agents Chemother. 2007; 51 (4): 1185–1190. doi: 10.1128/AAC.00809-06.Imbuluzqueta E., Elizondo E., Gamazo C., Moreno-Calvo E., Veciana J., Ventosa N. et al. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater. 2011; 7 (4): 1599–1608. doi: 10.1016/j.actbio.2010.11.031.Imbuluzqueta E., Elizondo E., Gamazo C., Moreno-Calvo E., Veciana J., Ventosa N. et al. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater. 2011; 7 (4): 1599–1608. doi: 10.1016/j.actbio.2010.11.031.Prior S., Gander B., Lecároz C., Irache J.M., Gamazo C. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. Antimicrob Chemother. 2004; 53 (6): 981–988. doi: 10.1093/jac/dkh227.Prior S., Gander B., Lecároz C., Irache J.M., Gamazo C. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. Antimicrob Chemother. 2004; 53 (6): 981–988. doi: 10.1093/jac/dkh227.Seleem M.N., Jain N., Pothayee N., Ranjan A., Riffle J.S., Sriranganathan N. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS Microbiol Lett. 2009; 294 (1): 24–31.doi: 10.1111/j.1574-6968.2009.01530.x.Seleem M.N., Jain N., Pothayee N., Ranjan A., Riffle J.S., Sriranganathan N. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS Microbiol Lett. 2009; 294 (1): 24–31.doi: 10.1111/j.1574-6968.2009.01530.x.Hosseini S.M., Farmany A., Abbasalipourkabir R., Asl S.S., Nourian A., Arabestani M.R. Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study. Ann Clin Microbiol Antimicrob. 2019; 18 (1): 33. doi: 10.1186/s12941-019-0333-xHosseini S.M., Farmany A., Abbasalipourkabir R., Asl S.S., Nourian A., Arabestani M.R. Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study. Ann Clin Microbiol Antimicrob. 2019; 18 (1): 33. doi: 10.1186/s12941-019-0333-xBodaghabadi N., Hajigholami S., Vaise Malekshahi Z., Entezari M., Najafi F., Shirzad H. et al. Preparation and evaluation of rifampicin and co-trimoxazole-loaded nanocarrier against Brucella melitensis. Infection. Iran Biomed J. 2018; 22 (4): 275–282. doi: 10.22034/ibj.22.4.275.Bodaghabadi N., Hajigholami S., Vaise Malekshahi Z., Entezari M., Najafi F., Shirzad H. et al. Preparation and evaluation of rifampicin and co-trimoxazole-loaded nanocarrier against Brucella melitensis. Infection. Iran Biomed J. 2018; 22 (4): 275–282. doi: 10.22034/ibj.22.4.275.Smith J.A., Khan M., Magnani D.D., Harms J.S., Durward M., Radhakrishnan G.K. Brucella induces an expanded protein response via TcpB, which supports intracellular replication in macrophages. PLoS Path [serial online]. 2013; 9 (12): e1003785. doi: 10.1371/journal.ppat.1003785.Smith J.A., Khan M., Magnani D.D., Harms J.S., Durward M., Radhakrishnan G.K. Brucella induces an expanded protein response via TcpB, which supports intracellular replication in macrophages. PLoS Path [serial online]. 2013; 9 (12): e1003785. doi: 10.1371/journal.ppat.1003785.Малецкая О.В. Влияние иммуномодулирующих препаратов на эффективность этиотропной терапии при экспериментальном хроническом бруцеллёзе. Иммунология. 2003; 24 (3): 182–184.Maletskaya O.V. The influence of immune-modeling drugs on the efficiency of etiotropic therapy in an experimental chronic brucellosis. Immunology. 2003; 24 (3): 182–184. (in Russian)].Патент РФ на изобретение №2239416/ 10.10.04. Малецкая О.В., Ефременко В.И., Таран Т.В., Лямкин Г.И., Ляпустина Л.В., Соколова И.А. Способ лечения бруцеллёза. Доступно по: javascript:load_article(37929353). Ссылка активна на 12.06.2020.Patent RUS №2239416/10.10.04. Maletskaja O.V., Taran T.V., Efremenko V.I., Ljamkin G.I., Sokolova I.A., Ljapustina L.V. Method for treatment of brucellosis. Dostupno po: javascript:load_article(37929353). Ssylka aktivna na 12.06.2020. (in Russian)]Патент РФ на изобретение №2234311/ 20.08.04. Малецкая О.В., Таран Т.В., Ефременко В.И., Лямкин Г.И., Соколова И.А., Ляпустина Л.В. Способ лечения бруцеллёза. Доступно по: javascript:load_article(37929353). Ссылка активна на 12.06.2020.Patent RUS №2234311/ 20.08.04. Maletskaja O.V., Taran T.V., Efremenko V.I., Ljamkin G.I., Sokolova I.A., Ljapustina L.V. Method for treatment of brucellosis. Dostupno po: javascript:load_article(37929353). Ssylka aktivna na 12.06.2020. (in Russian)]Irmak H., Buzgan T., Karahocagil M.K., Evirgen O., Akdeniz H., Demiröz A.P. The effect of levamisole combined with the classical treatment in chronic brucellosis. Tohoku J Exp Med. 2003; 201 (4): 221–228. doi: 10.1620/tjem.201.221.Irmak H., Buzgan T., Karahocagil M.K., Evirgen O., Akdeniz H., Demiröz A.P. The effect of levamisole combined with the classical treatment in chronic brucellosis. Tohoku J Exp Med. 2003; 201 (4): 221–228. doi: 10.1620/tjem.201.221.Reyes A.W.B., Vu S.H., Huy T.X.N., Min W., Lee H.J., Chang H.H. et al. The modulatory effect of linoleic acid during Brucella abortus 544 infection in a murine macrophage RAW264.7 cell and a murine model BALB/c mice. Microb Pathog. 2018; 119: 255–259.Reyes A.W.B., Vu S.H., Huy T.X.N., Min W., Lee H.J., Chang H.H. et al. The modulatory effect of linoleic acid during Brucella abortus 544 infection in a murine macrophage RAW264.7 cell and a murine model BALB/c mice. Microb Pathog. 2018; 119: 255–259.Motamedi H., Darabpour E., Gholipour M., Seyyed Nejad S.M. In vitro assay for the anti-Brucella activity of medicinal plants against tetracycline-resistant Brucella melitensis. J Zhejiang Univ Sci B. 2010; 11 (7):506–511. doi: 10.1631/jzus.B0900365.Motamedi H., Darabpour E., Gholipour M., Seyyed Nejad S.M. In vitro assay for the anti-Brucella activity of medicinal plants against tetracycline-resistant Brucella melitensis. J Zhejiang Univ Sci B. 2010; 11 (7):506–511. doi: 10.1631/jzus.B0900365.Arayan S.T., Simborio H.L., Reyes A.W., Hop H.T., Min W., Li H.J. The effect of red ginseng-a saponin fraction (RGSF-a) on phagocytosis and intracellular signaling in Brucella abortus infected RAW 264,7 cells. FEMS Microbiology Letters [serial online]. 2015 June; 362 (11). doi:10.1093/femsle/fnv070.Arayan S.T., Simborio H.L., Reyes A.W., Hop H.T., Min W., Li H.J. The effect of red ginseng-a saponin fraction (RGSF-a) on phagocytosis and intracellular signaling in Brucella abortus infected RAW 264,7 cells. FEMS Microbiology Letters [serial online]. 2015 June; 362 (11). doi:10.1093/femsle/fnv070.Reyes A.W., Simborio H.L., Hop H.T., Arayan L.T., Min W.G., Lee H.J. et al. Inhibiting effect of red ginseng acid polysaccharide from Korean red ginseng on phagocytic activity and intracellular replication of Brucella abortus in raw 264.7 cells. J Vet Sci. 2016; 17 (3): 315–321. doi:10.4142/jvs.2016.17.3.315.Reyes A.W., Simborio H.L., Hop H.T., Arayan L.T., Min W.G., Lee H.J. et al. Inhibiting effect of red ginseng acid polysaccharide from Korean red ginseng on phagocytic activity and intracellular replication of Brucella abortus in raw 264.7 cells. J Vet Sci. 2016; 17 (3): 315–321. doi:10.4142/jvs.2016.17.3.315.Huy T.X., Reyes A.W., Hop H.T., Arayan L.T., Min W., Li H.J. Intracellular modulation of ginsenoside Rg3 trafficking inhibits the uptake of abortus Brucella and intracellular survival within raw 264.7 cells. J Microbiol Biotechnol. 2017; 27 (3): 616–623. doi: 10.4014/jmb.1609.09060.Huy T.X., Reyes A.W., Hop H.T., Arayan L.T., Min W., Li H.J. Intracellular modulation of ginsenoside Rg3 trafficking inhibits the uptake of abortus Brucella and intracellular survival within raw 264.7 cells. J Microbiol Biotechnol. 2017; 27 (3): 616–623. doi: 10.4014/jmb.1609.09060.Naghdi N., Hassanzadazar H., Delpisheh A. The most important medicinal plants for the treatment of brucellosis. J Prev Epidemiol. 2016; 1 (2): e30.Naghdi N., Hassanzadazar H., Delpisheh A. The most important medicinal plants for the treatment of brucellosis. J Prev Epidemiol. 2016; 1 (2): e30.

The authors declare that there are no conflicts of interest present.